文献速递肥胖与代谢综合征糖尿病

偏向性GLP-1受体激动剂埃诺格鲁肽治疗超重或肥胖成人的疗效与安全性:一项多中心、随机、双盲、安慰剂对照3期试验

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-06-21

该3期试验在中国36个中心纳入664例无糖尿病的超重或肥胖成人,随机接受每周一次埃诺格鲁肽1.2、1.8、2.4 mg或安慰剂。第40周时,埃诺格鲁肽各剂量组体重降幅及≥5%减重比例均优于安慰剂,不良事件以轻中度胃肠道反应为主。

要点

  • 埃诺格鲁肽1.2、1.8、2.4 mg组第40周体重最小二乘均值降幅分别为9.1%、10.9%、13.2%,安慰剂组为0.1%。
  • 埃诺格鲁肽1.2、1.8、2.4 mg组≥5%减重比例分别为77%、84%、87%,安慰剂组为16%。
  • 治疗中出现的不良事件发生率在埃诺格鲁肽组均为93%,安慰剂组为84%,多为轻中度胃肠道事件。

核心结论

  • 在无1型或2型糖尿病的超重或肥胖成人中,埃诺格鲁肽较安慰剂带来更优且持续的体重下降,安全性良好,支持其用于体重管理的潜在价值。

研究设计与样本

  • 在中国36个医疗中心开展的随机、双盲、安慰剂对照3期试验,纳入18-75岁超重或肥胖且无糖尿病的成人。
  • 2023年4月5日至2024年6月20日筛查882人,随机分配664人至埃诺格鲁肽1.2 mg(n=166)、1.8 mg(n=166)、2.4 mg(n=167)或安慰剂(n=165),按筛查时BMI分层。
  • 主要终点为第40周体重百分比变化和体重降低≥5%的受试者比例,采用治疗策略估计目标的全分析集。

主要发现

  • 第40周体重最小二乘均值百分比变化:埃诺格鲁肽1.2 mg组-9.1%(SE 0.8)、1.8 mg组-10.9%(SE 0.9)、2.4 mg组-13.2%(SE 0.8),安慰剂组0.1%(SE 0.8)。
  • 与安慰剂估计治疗差异分别为-9.2%(97% CI -11.0至-7.5)、-11.1%(97% CI -13.1至-9.1)、-13.3%(97% CI -15.3至-11.3),均p<0.0001。
  • 第40周体重降低≥5%的比例:埃诺格鲁肽1.2 mg组77%、1.8 mg组84%、2.4 mg组87%,安慰剂组16%;与安慰剂估计治疗差异分别为60%(98% CI 50至71)、68%(98% CI 58至78)、70%(98% CI 61至80),均p<0.0001。
  • 治疗中出现的不良事件:埃诺格鲁肽1.2 mg组155/166(93%)、1.8 mg组154/166(93%)、2.4 mg组156/167(93%),安慰剂组139/165(84%);最常见为轻中度胃肠道相关事件。
  • 因不良事件停用埃诺格鲁肽者共10例。

临床怎么用

  • 原文结论认为,埃诺格鲁肽较安慰剂带来更优且持续的体重下降且安全性良好,支持其用于体重管理的潜在价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ecnoglutide is a novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist currently in development for weight management. We aimed to assess the efficacy and safety of once weekly ecnoglutide versus placebo for the treatment of overweight or obesity in Chinese adults. METHODS: This randomised, double-blind, placebo-controlled, phase 3 trial was done at 36 medical centres across China. Eligible adults were aged 18-75 years with overweight or obesity (defined as BMI ≥28 kg/m2 or ≥24 kg/m2 with at least one weight-related comorbidity [prediabetes, hypertension, hyperlipidaemia, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnoea syndrome, or weight-bearing joint pain]), without diabetes (type 1 or 2). Participants were randomly assigned (3:3:3:1:1:1) via computer-generated random sequencing to receive subcutaneous ecnoglutide (1·2, 1·8, or 2·4 mg) or volume-matched placebo (1·2, 1·8, or 2·4 mg), once weekly, stratified by BMI at screening (≥28 kg/m2 and <28 kg/m2). The coprimary endpoints were percentage change in bodyweight and proportion of participants with a reduction in bodyweight of 5% or more at week 40 (using the treatment policy estimand in the full analysis set). The full analysis set included all randomly assigned participants who were exposed to at least one dose of study drug or placebo according to their assigned treatment group. Safety was assessed in all participants who received at least one dose and had a safety assessment after medication. This study was registered with ClinicalTrials.gov, NCT05813795, and is complete. FINDINGS: Between April 5, 2023, and June 20, 2024, 882 participants were screened and 664 were randomly assigned to receive ecnoglutide 1·2 mg (n=166), ecnoglutide 1·8 mg (n=166), ecnoglutide 2·4 mg (n=167), or placebo (n=165). At week 40, the least-squares mean percentage change in bodyweight was -9·1% (SE 0·8) in the ecnoglutide 1·2 mg group, -10·9% (0·9) in the ecnoglutide 1·8 mg group, and -13·2% (0·8) in the ecnoglutide 2·4 mg group versus 0·1% (0·8) in the placebo group, and the respective estimated treatment differences compared with placebo were -9·2% (97% CI -11·0 to -7·5), -11·1% (-13·1 to -9·1), and -13·3% (-15·3 to -11·3), respectively (all p<0·0001). The proportion of participants who achieved at least a 5% reduction in bodyweight at week 40 was 77% in the ecnoglutide 1·2 mg group, 84% in the ecnoglutide 1·8 mg group, and 87% in the ecnoglutide 2·4 mg group versus 16% of participants in the placebo group, and the respective estimated treatment differences versus placebo were 60% (98% CI 50 to 71), 68% (58 to 78), and 70% (61 to 80; all p<0·0001). Treatment-emergent adverse events were observed in 155 (93%) of 166 participants in the ecnoglutide 1·2 mg group, 154 (93%) of 166 participants in the ecnoglutide 1·8 mg group, 156 (93%) of 167 participants in the ecnoglutide 2·4 mg group, and 139 (84%) of 165 participants in the placebo group. The most common adverse events were mild-to-moderate gastrointestinal related events. Ten participants treated with ecnoglutide discontinued treatment due to adverse events. INTERPRETATION: In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety profile, supporting its potential use for weight management. FUNDING: Hangzhou Sciwind Biosciences.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Ji L, Gao L, Xue H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025. PMID: 40555243. doi:10.1016/S2213-8587(25)00141-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。